Therapeutic | Lanadelumab |
Target | KLKB1 |
Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSS |
Light Chain | DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK |
100% seqID Fv Structure | 4ogx [Fvs: HL], 4ogy [Fvs: HL, MN], 4pub [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4pub [Fvs: HL] |
100% seqID Structure | 4ogy [Fvs: HL, MN] |
100% seqID Structure | 4ogx [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | NFD |
Recorded Developmental Technology | na |
INN Year Proposed | 2015 |
INN Year Recommended | 2016 |
Companies Involved | Dyax, Shire, Takeda |
Conditions Approved | Hereditary angioedema |
Conditions Active | na |
Conditions Discontinued | Diabetic macular oedema |
Notes |